Should I wait until July 1, 2026 to start the process?

It is better to start now. The Bridge has specific clinical criteria, and prior authorization is a paperwork process that involves a clinical visit, documentation, and plan-side review. If you meet the criteria, having your prescriber file early means you are less likely to wait in a launch-day backlog. If you don't meet the criteria today, you have time to talk with your prescriber about other paths before July. The GLP Winner provider survey is one place to start the search for a provider who can do the evaluation and handle the paperwork.

Should I just hold off on starting a GLP-1 until July?

Holding off is rarely the cheapest or fastest move. If you can afford a GLP-1 today through insurance, a savings card, or a direct-to-consumer cash program, starting now and switching to the $50 Medicare Bridge in July (if you qualify) keeps you from losing months of treatment progress. If you cannot afford to start today, finding a provider now and having your evaluation done before July puts you ahead of the launch-day backlog. The thing to avoid is doing nothing while you wait, only to find out in July that you don't qualify or that your PCP is not set up for the prior authorization.

Do I have to use my regular primary care doctor?

No. Your PCP can evaluate you and file prior authorization, but you are not limited to that path. The GLP Winner provider survey can match you with telehealth providers and obesity specialists who work directly with Medicare Part D plans and handle the prior authorization workflow for FDA-approved GLP-1 medications. If your PCP doesn't typically manage these prescriptions or has a long wait for an appointment, finding a provider through the survey is a way to keep the process moving.

Will I really pay $50 a month for a GLP-1 on Medicare?

If you are a Medicare Part D beneficiary, your prescriber confirms you meet the clinical criteria, prior authorization is filed and approved, and your medication is one of the three covered under the Bridge (Wegovy, Zepbound, or Foundayo), then yes, the copay is $50 per month starting July 1, 2026. The Bridge runs through December 31, 2027 unless extended.

What if I'm on Ozempic or Mounjaro?

Ozempic and Mounjaro are not directly in the Medicare GLP-1 Bridge. The administration negotiated separate pricing arrangements for those medications. Talk to your Part D plan about your specific coverage and copay, and to your prescriber about whether a switch to a Bridge-covered medication is appropriate for your situation.

Does the $50 copay count toward my Part D deductible?

No. The $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket maximum. It stays at $50 per month regardless of which benefit phase you are in during the year.

What if I'm not on Medicare?

The $50 figure is a Medicare Part D program. It does not apply to commercial insurance, Medicaid, or uninsured patients. If that is your situation, the broader GLP-1 pricing landscape still applies: manufacturer savings cards, direct-to-consumer cash programs, and licensed compounded medications are all options to discuss with your prescriber.

What happens after December 31, 2027?

The Bridge is a demonstration program with a planned end date. Whether it is extended, expanded, or replaced with permanent Medicare coverage will depend on policy decisions by the administration and Congress. Patients enrolled today should plan for the possibility that the $50 copay may not continue in its current form past 2027.

What Medicare's $50 GLP-1 Plan Actually Means

Starting July 1, 2026, certain Medicare Part D beneficiaries will be able to get specific FDA-approved GLP-1 medications for $50 per month under a new federal program, but the eligibility, the medication list, and the timeline come with details that matter (Reuters).

The program is called the Medicare GLP-1 Bridge, and it runs as a temporary demonstration from July 1, 2026, through December 31, 2027 (CMS). Like most Medicare programs, the eligibility rules, the covered drug list, and the prior authorization steps shape who actually pays $50 and who does not. The most common mistake we see is patients reading a headline like "$50 GLP-1s" and going passive: holding off on starting a medication, holding off on finding a provider, and assuming July will sort itself out. It usually does not. This article walks through what the program does, who is in and out, and what to do now so July is a switch-over, not a starting line.

Corrections made May 13th, 2026: An earlier version of this article was published that may have made it seem you could submit prior authorization (PA) through your provider before July 1st, 2026. This is not the case, but you can take action to ensure you're provider is prepared to submit the PA once the submission process is live. Edits have been made to make this more clear, with more specific information about the PA process added, and how to understand if you're in an eligible plan. Please reach out to if you have any questions.

Who This Helps

You are a Medicare beneficiary on Wegovy, Zepbound, or another GLP-1 and want to know if your costs will drop.
You have been considering a GLP-1 for weight loss but have been priced out, and Medicare is your insurance.
You are about to age into Medicare and want to know how the new $50 program affects your options.
You are helping a parent or partner sort out whether they qualify.
You have been holding off on starting a GLP-1 because you saw the news about $50 Medicare pricing and figured you'd wait for July.
You are not on Medicare and want to understand whether the $50 number applies to you (it does not, and that matters for what you do next).

What "$50 Medicare GLP-1" Actually Means

The $50 number is a copay, not a price cut to the medication itself. The federal government negotiated with the manufacturers to supply the medications at a lower net price (about $245 per month in the case of Wegovy and Zepbound), and the patient share at the pharmacy counter sits at $50 (CMS, KFF).

A few mechanics that matter:

The $50 copay does not count toward your Part D deductible or your $2,100 out-of-pocket maximum for the year (KFF).
The copay stays at $50 per month regardless of which Part D benefit phase you're in.
The program is open to beneficiaries enrolled in eligible Part D plan types, with the central processor (Humana) handling prior authorization, claims, and payments to pharmacies on behalf of CMS rather than the patient's Part D plan.
It is a demonstration program with a planned end date of December 31, 2027, unless extended (CMS).

Why to Start the Process Now, Not Wait Until July

If the $50 figure caught your attention and you're thinking about waiting until July 1, 2026, to start the conversation, the honest answer is that waiting may cost you. The Bridge has specific clinical criteria and a prior authorization process, and the gap between "I want to be on this" and "my prescriber has filed paperwork that's been approved" is rarely instant.

A few practical reasons to start the work now:

Confirming eligibility takes a clinical assessment. Your prescriber has to document your body mass index, your conditions, and the rationale for treatment. That visit takes time to schedule and complete.
Prior authorization is a paperwork process, not a button-press. The first wave of Bridge prior authorizations will create a backlog at the central processor that CMS contracted to run the program, and being early in the queue helps you avoid weeks of delay at the pharmacy counter. Your provider cannot submit a prior authorization now, but starting the discussion as soon as possible means they can be ready to file the moment the processor opens on July 1, 2026.
Finding the right prescriber matters. Not every clinician treats obesity or weight management, and not every telehealth service is set up for Medicare prior authorization workflows.
If you don't meet the clinical criteria today, knowing that early lets you and your prescriber discuss other options well before July, instead of finding out at the counter.

You can start with the doctor you already see. Under the Bridge rules, the provider who writes your prescription does not need to be enrolled in Medicare. They just need to be licensed and not barred from Medicare, which is a short federal exclusion list that most providers are not on (CMS). That means your regular primary care doctor, a nurse practitioner, a physician assistant, or an obesity or endocrinology specialist can usually handle it.

If your usual doctor does not prescribe GLP-1 medications, another licensed provider can step in, though availability varies and not every telehealth practice is taking Medicare patients. That is exactly why it helps to start the conversation early. Booking now lines up your pre-qualifications and puts you near the front when submissions begin, rather than scheduling a first visit in July alongside everyone else who waited.

How the Prior Authorization Actually Works

The Bridge prior authorization process is different from a normal Part D prior authorization, and the difference matters for how you prepare.

Bridge prior authorizations do not go to your Part D plan. CMS contracted a single central processor (Humana, which already runs the LI NET program for Medicare) to handle all Bridge prior authorizations, claims, and payments to pharmacies (NCPA). Your prescriber submits the request directly to that processor.

The processor is scheduled to begin accepting submissions on July 1, 2026, the same day the Bridge launches (Reed Smith). CMS is still publishing the technical instructions providers need, and pharmacies are still being briefed on which claims go to the plan and which go to the central processor. Operational friction in July and August is realistic.

What this means for you: you cannot have a Bridge prior authorization filed in May or June. You can have your clinical evaluation done, your eligibility documented, your prescription drafted, and your prescriber lined up so that the submission goes in on day one. That is what "start the process now" actually means.

Two Paths to Consider Right Now

If the $50 figure has you thinking, the most useful move you can make today is to choose between two paths. Both involve action now, and both work whether you are already on Medicare or not.

Path one: start now, switch to $50 in July. If your insurance, your manufacturer savings card, or a direct-to-consumer cash program makes a GLP-1 affordable today, you can start the medication now under your current pricing and have it shipped to your door. When July arrives, that same provider can re-evaluate you for the Medicare GLP-1 Bridge if you qualify, and your monthly cost can drop to $50. You don't lose months of treatment progress while waiting for a launch date.

Path two: line up your provider now, start at $50 in July. If today's pricing is out of reach but the $50 Medicare price is in budget, the move is to find your provider now and have your evaluation done before July. When the Bridge launches, your prior authorization is ready to file, your prescription is ready to fill, and you are not in the launch-day backlog with everyone else who waited. Call or check online to find a provider covered under your plan to begin the conversation.

The thing both paths share: figure out now whether you would even be eligible under the Bridge if July were today. Knowing your answer in May, not in July, is what lets you make a real plan instead of a hopeful one.

Who Qualifies, Specifically

The Bridge is targeted, not universal. To get the $50 copay, a Medicare Part D beneficiary needs to meet specific clinical criteria, get a prescription that attests to the use, and clear prior authorization (CMS):

Body mass index of 35 or higher, OR
Body mass index of 30 or higher with one of these conditions: heart failure with preserved ejection fraction, uncontrolled hypertension (systolic blood pressure over 140 or diastolic over 90 on at least two medications), or chronic kidney disease at stage 3a or higher, OR
Body mass index of 27 or higher with pre-diabetes or a prior heart attack.
Beneficiary aged 18 or older.
Prescription must attest that the medication is being used for weight reduction along with lifestyle changes per the FDA-approved label.

If you started a GLP-1 before becoming Medicare-eligible, you can still qualify if you met the clinical criteria when therapy started. The prior authorization process is what your prescriber files; you do not file it yourself.

Which Medications Are In, and Which Are Not

As of the July 1, 2026, launch, the Medicare GLP-1 Bridge covers these specific medications:

Wegovy. All formulations, including the injectable and the Wegovy Pill (oral semaglutide for chronic weight management).
Zepbound. The KwikPen formulation.
Foundayo (orforglipron). All formulations of the FDA-approved oral GLP-1, approved in April 2026.

These medications are notable for what's not on the list:

Ozempic and Mounjaro are not directly in the Bridge program. The administration negotiated separate pricing arrangements for those medications, and Medicare patients should check with their plan for current coverage and copay details.
Compounded GLP-1 medications are not covered under the Bridge. The program is for FDA-approved finished drugs only (FDA).
Original Medicare (Parts A and B) and Medicare Advantage plans are not part of the Bridge. The $50 copay applies to Part D enrollment specifically.

What This Changes From How Things Work Now

Before the Bridge, Medicare did not cover GLP-1 medications for weight loss. Coverage was limited to GLP-1s prescribed for type 2 diabetes (and even there, with prior authorization and step-therapy requirements). Patients on a weight-loss-only prescription typically paid the full cash list price, often more than $1,000 per month for a brand-name medication.

The Bridge adds a new pathway. For Part D beneficiaries who meet the clinical criteria above, a covered medication's monthly cost becomes $50, and the prior authorization process is the gate. None of this changes what licensed compounding pharmacies have been doing under federal pharmacy law, and none of it formalizes a permanent expansion of Medicare coverage. It is a time-limited demonstration. The longer GLP Winner overview of Medicare GLP-1 coverage starting July 2026 walks through what eligible patients should expect at the pharmacy counter.

What's Still in Motion

A few pieces of the picture are still being filled in, and patients should track them:

Prior authorization workflows are new to everyone involved. Expect a few months of operational friction at the pharmacy counter as the central processor, pharmacies, and prescribers all learn the process.
The Bridge sunsets on December 31, 2027, unless extended. A permanent expansion is not in place.
Original Medicare and Medicare Advantage plans may add separate coverage in their own time, with their own rules. The Bridge is Part D only.
Lilly committed to 'more than $50 billion in U.S. manufacturing' as part of the agreement, which builds on the company's 2025 'Lilly in America' plan of $27 billion in new manufacturing investments (Lilly). Novo Nordisk's separate manufacturing commitments tied to the deal have been reported in secondary coverage but are not yet confirmed in a Novo Nordisk primary source we have been able to locate.
Direct-to-consumer cash-pay programs from the manufacturers are running alongside the Medicare program. The GLP Winner walk-through of the new federal direct-to-consumer prescription site covers what to read before signing up to those.

What to Do If You're a Medicare Patient on a GLP-1

If you are already on Wegovy, Zepbound, or Foundayo through Medicare Part D, or you think you may qualify, the practical sequence:

Start now, not in July. Schedule a clinical evaluation in the next several weeks to confirm whether you meet the Bridge eligibility criteria. If you qualify, your prescriber can have prior authorization filed and ready to process starting on July 1st, 2026. If you don't qualify today, you'll know early enough to plan and discuss alternatives with your provider.
Find a provider set up for this (you don't have to use your PCP). Your insurance plan website or support team can match you with telehealth providers and obesity specialists who accept Medicare Part D, handle prior authorization workflows, and publish their evaluation criteria up front.
Confirm you are enrolled in an eligible Part D plan type. Stand-alone Part D drug plans (PDPs) and Medicare Advantage plans with prescription drug coverage that are HMO, HMO-POS, Local PPO, or Regional PPO are eligible. Three ways to check, in order of ease: look at your insurance cards (a separate prescription drug plan card from a private insurer usually means a stand-alone PDP; a single card covering medical and drugs together usually means MA-PD), log in at MyMedicare.gov to see your current plan, or call 1-800-MEDICARE (1-800-633-4227) and ask. If your plan is not eligible, your local State Health Insurance Assistance Program (SHIP) office can walk you through your options.
Talk with your prescriber about whether you meet the clinical criteria and discuss with them your desire to enroll in the Bridge program as soon as possible if you qualify. They will be able to better anticipate the prior authorization process when they can submit it starting on July 1st. The earlier the paperwork goes in, the less likely you are to wait in a launch-day backlog.
If you are switching from another GLP-1, ask whether the alternative is a covered medication under the Bridge, or whether your prescriber needs to write a new prescription.
Keep your pharmacy benefit notices. The first few months may include processing changes, and a paper trail helps.
If your situation does not fit the Bridge criteria, ask your prescriber about other options, including the longer GLP Winner overview of how insurance coverage for GLP-1s really works for a broader picture of where else costs are moving.

What to Do If You're Not on Medicare (Yet)

The $50 figure does not extend to commercial insurance, Medicaid, or uninsured patients automatically. If you are not on Medicare and have been holding off because of the news, the most useful move is the same as for Medicare patients: pick a path and start now. The rest of the GLP-1 pricing landscape still applies:

Manufacturer savings cards remain the cheapest path with commercial insurance, often around $25 per month.
Direct-to-consumer cash programs from the manufacturers run a few hundred dollars per month for some doses. The longer GLP Winner breakdown of why GLP-1 costs tend to go up after you start covers the pricing patterns to watch for.
Compounded GLP-1 medications through licensed pharmacies remain a path some patients take with their prescriber. The GLP Winner pharmacy directory lets you filter by state, by 503A or 503B status, by additive, and read patient reviews.
The GLP Winner provider survey connects you with options that publish clinician names, pharmacy details, and pricing up front, regardless of which path you end up on. Please be aware, FDA-approved providers typically only work with commercial insurance plans.

Where Compounded GLP-1s Fit Into the Picture

Compounded GLP-1 medications are not part of the Medicare GLP-1 Bridge. The Bridge covers FDA-approved finished drugs only. Compounded GLP-1 medications are made by licensed 503A or 503B compounding pharmacies based on a prescription from a licensed clinician, and they remain a path that some patients and clinicians choose together for reasons that may not be primarily about Medicare cost (FDA). The longer GLP Winner overview of 503A and 503B compounding pharmacies walks through the framework.

Final Takeaway

If you are a Medicare Part D beneficiary who qualifies, the Bridge program is a meaningful change. A medication that may have been $1,000-plus per month becomes $50 per month, with prior authorization, starting July 1, 2026. The eligibility criteria are specific, the medication list is targeted, and the program ends December 31, 2027, unless renewed.

The thing the headlines don't say is what to do between now and July. The two practical paths are: start a GLP-1 today at your current pricing and switch to $50 in July if you qualify, or line up your provider now and start at $50 on launch day. Both require finding a provider who handles Medicare Part D prior authorization, and that provider does not have to be your usual primary care doctor.

If you are not on Medicare, the headline number does not apply directly to you, but the broader pricing landscape has shifted. Direct-to-consumer programs, savings cards, and licensed compounded paths are all in play.

The mistake we see most often is staying still while waiting for July. Whichever path fits your situation, start the work this month. By July, the difference between people who acted now and people who waited will look like weeks of treatment, weeks at the lower price, or weeks of paperwork delay.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

What Medicare's $50 GLP-1 Plan Actually Means for You

Who This Helps

What "$50 Medicare GLP-1" Actually Means

Why to Start the Process Now, Not Wait Until July

How the Prior Authorization Actually Works

Two Paths to Consider Right Now

Who Qualifies, Specifically

Which Medications Are In, and Which Are Not

What This Changes From How Things Work Now

What's Still in Motion

What to Do If You're a Medicare Patient on a GLP-1

What to Do If You're Not on Medicare (Yet)

Where Compounded GLP-1s Fit Into the Picture

Final Takeaway

Sources

Keep Reading

GLP-1 Coverage in 2026: What Medicare, Insurance, and Policy Signals Really Mean

Medicare Will Cover GLP-1 Weight Loss Drugs Starting July 2026: What You Need to Know

Medicare, GLP-1s, and TrumpRx: What You Need To Know

Trump’s $150 Ozempic Plan: What’s Real (and What’s Not)

Categories

Curated by

GLP Winner Assistant